Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.52 |
| ▸ | GSK3B | P49841 | 13/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849394 | 0.84 | CES2 (0.56) | PTPN1GSK3BCES2CES1 | |
| SCHEMBL16600782 | 0.83 | PTPN1 (0.52) | PTPN1GSK3BCES2CES1 | |
| SCHEMBL3549232 | 0.81 | MAPT (0.50) | CES2CES1HDAC1HDAC6 | |
| SCHEMBL20819692 | 0.81 | HDAC1 (0.52) | PTPN1GSK3BCES2CES1HDAC1 | |
| SCHEMBL18355570 | 0.81 | GSK3B (0.43) | GSK3BCES2CES1HDAC1HDAC6 | |
| SCHEMBL23112490 | 0.81 | GSK3B (0.50) | PTPN1GSK3BCES2CES1 | |
| SCHEMBL18629793 | 0.80 | PTPN1 (0.46) | PTPN1GSK3B | |
| SCHEMBL11642081 | 0.79 | HDAC1 (0.46) | PTPN1GSK3BHDAC1HDAC6 | |
| SCHEMBL6543881 | 0.78 | GSK3B (0.59) | PTPN1GSK3B | |
| SCHEMBL2953875 | 0.78 | PTPN1 (0.57) | PTPN1GSK3BCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | PTPN1 1287/4885GSK3B 2725/4885CES2 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.